<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04234412</url>
  </required_header>
  <id_info>
    <org_study_id>UC19OISI0134</org_study_id>
    <nct_id>NCT04234412</nct_id>
  </id_info>
  <brief_title>Treatment of Osteoarthritic Knee With High Tibial Osteotomy and Implantation of Allogenic Human Umbilical Cord Blood-derived Stem Cells.</brief_title>
  <official_title>Treatment of Osteoarthritic Knee With High Tibial Osteotomy and Implantation of Allogenic Human Umbilical Cord Blood-derived Stem Cells.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uijeongbu St. Mary Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Uijeongbu St. Mary Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the clinical results after implantation of human
      umbilical cord blood-derived mesenchymal stem cells(hUCB-MSCs) and High tibia osteotomy in
      patients with medial compartment osteoarthritis(MCOA) as well as varus deformity of the knee
      joint.

      This study will prospectively evaluate 10 knees after hUCB-MSCs implantation and High Tibial
      Osteotomy(HTO) in the medial compartment osteoarthritis and varus deformity of the knee
      joint.

      Clinical outcomes will be evaluated using the International Knee Documentation
      committee(IKDC), Visual analogue scale(VAS), Western Ontario and McMaster Universities
      Arthritis Index(WOMAC), and patients satisfaction with the surgery.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>only case series of the treated patients</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>International Cartilage Repair Society (ICRS) grade improvement</measure>
    <time_frame>at 24, 48, 96 weeks after surgery, score changes will be observed.</time_frame>
    <description>over grade 1 should be improved</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual analogue scale (VAS)</measure>
    <time_frame>at 24, 48, 96 weeks after surgery, score changes will be observed.</time_frame>
    <description>0-10 score range, lower the better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Western Ontario and McMaster Universities Arthritis Index (WOMAC)</measure>
    <time_frame>at 24, 48, 96 weeks after surgery, score changes will be observed.</time_frame>
    <description>0-100 score range, lower the better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Knee Documentation Committee (IKDC score)</measure>
    <time_frame>at 24, 48, 96 weeks after surgery, score changes will be observed.</time_frame>
    <description>0-100 % range, lower the better</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Osteoarthritic knee patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Osteoarthritic Knee of the patients who will be treated wth high tibial osteotomy and implantation of allogenic human umbilical cord blood-derived stem cells.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>umbilical cord blood stem cell implantation for osteoarthritis treatment</intervention_name>
    <description>The arthroscopic procedure is performed in the supine position after spinal anesthesia. Once the chondral lesion is identified through a standard anteromedial and lateral portal, meniscectomy, meniscal repair, and lateral retinacular release are performed if necessary. microfracture is performed using a microfracture awl.
Once both the unstable cartilage and subchondral bone are removed in the lesion area and the sclerotic bone is peeled slightly by using a burr, hole(s) are created for implantation by using a drill bit(diameter 4; depth: 4mm). After implantation is performed in the hole by injecting the mixture of sodium hyaluronate and hUCB-MSCs, it is trimmed to the height of the surrounding articular surface.</description>
    <arm_group_label>Osteoarthritic knee patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age older than 30 years,

          -  full-thickness cartilage lesion measuring at least 2 cm2,

          -  femoro-tibial angle (varus or valgus) 5Â°&lt; in the mechanical axis

        Exclusion Criteria:

          -  ligament injuries (such as injuries of the anterior cruciate ligament and posterior
             cruciate ligament),

          -  metabolic arthritis

          -  infectious condition

          -  psychosis

          -  serious medical illness

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 5, 2020</study_first_submitted>
  <study_first_submitted_qc>January 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 21, 2020</study_first_posted>
  <last_update_submitted>January 15, 2020</last_update_submitted>
  <last_update_submitted_qc>January 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Uijeongbu St. Mary Hospital</investigator_affiliation>
    <investigator_full_name>Seckjung Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>osteoarthritis</keyword>
  <keyword>knee</keyword>
  <keyword>high tibial osteotomy</keyword>
  <keyword>umbilical cord blood stem cell</keyword>
  <keyword>cartilage regeneration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>according to patient agreement, this is flexible.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

